Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Value communications

National Institute for Health and Care Excellence NICE logo

NICE consults on value-based assessment changes

Aims to create a more flexible approach to drug funding decisions for NHS in England and Wales

Lilly launches online training to boost patient voice in HTA

New tool aims to help patient advocates 'better influence decisions'

- PMLiVE

Ireland and the impact of reference pricing

Industry remains tight-lipped on the country's pharmaceutical pricing changes

- PMLiVE

No price ceiling for rare disease drugs, say MPs

BIA survey comes ahead of consultation on evaluation framework for ultra-orphans

NICE and ‘ultra orphans’

NICE and its processes for ‘highly specialised therapies’

- PMLiVE

Compulsory evaluation in France

French authorities will expect robust health economic cases to be made for some drugs

- PMLiVE

Biosimilars: friend or foe for healthcare systems?

An opportunity in Europe, but widespread acceptance and uptake is by no means a done deal

- PMLiVE

Value-based assessment

NICE is set to modify the way it operates, but the changes shouldn’t come as a surprise

Define the patient burden in rare diseases

Putting patients and carers at the heart of the value demonstration equation in orphan drugs is key

- PMLiVE

EU gives boost to its network of HTA bodies

EUnetHTA strengthens role in market access in EU

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

Orphan indication? No easy access

Health technology assessment for orphan drugs continues to present challenges for pharmaceutical companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links